Illustrative

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval

BioSpace·Dec 24

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Lilly has received a landmark approval for a glp-1 treatment related to sleep apnea. The approval was granted by the end of 2024. The treatment is considered a significant development, with details of the approval still emerging.

Full coverage

Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial

Fierce Pharma·Jul 31

Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea

Fierce Pharma·Dec 20

Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData

Fierce Pharma·Jan 2

View original report at BioSpace ↗

Fetching the latest headlines…

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval

Full coverage

Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial

Lilly's Zepbound scores 2nd approval with landmark FDA nod in obstructive sleep apnea

Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData